Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is a global healthcare company with a broad portfolio of advanced wound care, surgical, dental, and healthcare software products. Management has taken decisive steps to unlock value for shareholders, including divesting non-core businesses and initiating a shareholder-friendly capital return program. Further, the announced intent to separate the HIS segment highlights management's commitment to shareholder value creation and offers a potential catalyst for the stock. While there are some risks to consider, such as competition and potential dilution from the separation, the fundamental factors and strategic initiatives support a positive outlook on Solventum's stock.

Bears say

Solventum is facing challenges with the separation of their HIS segment and negative organic growth, with a decrease in Q3 organic growth by 3-4% and a flat organic growth for H2 2026. The company has made minor adjustments to their financials, with an increase in FY26 guidance for organic growth to 2.5%-3.0%. However, there has been a decrease in MedSurg OMs despite growth driven by differentiated and higher-value products.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.